Meeting
2021 ASCO Annual Meeting
Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study.
Authors
Rahul Raj Aggarwal
University of California, San Francisco, San Francisco, CA
Rahul Raj Aggarwal , Srey Luch Sam , Vadim S Koshkin , Eric Jay Small , Felix Y Feng , Ivan de Kouchkovsky , Daniel H Kwon , Terence W. Friedlander , Hala Borno , Rohit Bose , Jonathan Chou , Arpita Desai , Tammy J. Rodvelt , Maya Aslam , Medini Rastogi , Lawrence Fong , Thomas A Hope
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03805594
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5053)
DOI
10.1200/JCO.2021.39.15_suppl.5053
Abstract #
5053
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
First Author: Henry Jacob Conter
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
First Author: Srikala S. Sridhar
Poster
2022 ASCO Genitourinary Cancers Symposium
BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Benedito A. Carneiro
Poster
2020 ASCO Virtual Scientific Program
KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).
First Author: Christopher J. Hoimes